- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
α‐Triazolylboronic Acids: A Novel Scaffold to Target FLT3 in AML ; day:09 ; month:11 ; year:2024 ; extent:11
ChemMedChem ; (09.11.2024) (gesamt 11)
- Creator
-
Introvigne, M. L.
Destro, L.
Mologni, L.
Crippa, V.
Zardi, P.
Fini, F.
Prati, L. F.
Caselli, E.
Zambon, A.
- DOI
-
10.1002/cmdc.202400622
- URN
-
urn:nbn:de:101:1-2411091418414.678553364545
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:31 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Introvigne, M. L.
- Destro, L.
- Mologni, L.
- Crippa, V.
- Zardi, P.
- Fini, F.
- Prati, L. F.
- Caselli, E.
- Zambon, A.
Other Objects (12)
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML
FLT3-ITD regulated miRs in AML
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
Dendritic cell dysfunctions in AML patients with FLT3 ITD mutations
Effekte von FLT3-ITD Inhibitoren auf Chemotherapie resistente AML Zelllinien
Dendritic Cell dysfunctions in AML patients with FLT3 ITD mutations
Charakterisierung von AML-assoziierten FLT3-Rezeptortyrosinkinasemutanten im Zell- und Mausmodell
Nachweis von NPM1- und FLT3-Mutationen bei Patienten mit AML
Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD–positive AML
Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML
FLT3-ITD regulated miRs in AML
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
Dendritic cell dysfunctions in AML patients with FLT3 ITD mutations
Effekte von FLT3-ITD Inhibitoren auf Chemotherapie resistente AML Zelllinien
Dendritic Cell dysfunctions in AML patients with FLT3 ITD mutations
Charakterisierung von AML-assoziierten FLT3-Rezeptortyrosinkinasemutanten im Zell- und Mausmodell
Nachweis von NPM1- und FLT3-Mutationen bei Patienten mit AML
Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD–positive AML
Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML
FLT3-ITD regulated miRs in AML
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
Dendritic cell dysfunctions in AML patients with FLT3 ITD mutations
Effekte von FLT3-ITD Inhibitoren auf Chemotherapie resistente AML Zelllinien
Dendritic Cell dysfunctions in AML patients with FLT3 ITD mutations
Charakterisierung von AML-assoziierten FLT3-Rezeptortyrosinkinasemutanten im Zell- und Mausmodell
Nachweis von NPM1- und FLT3-Mutationen bei Patienten mit AML
Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD–positive AML
Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors